Baxter downgraded to In Line on valuation at Evercore ISI. As previously reported, Evercore downgraded Baxter to In Line from Outperform with an $84 price target. Analyst Vijay Kumar views valuation as “fair at current levels” following multi-year outperformance.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.